ArticleMaterials today. Bio2025
Immunomodulating platelet-mimicking nanoparticles for AIE-based enhanced photodynamic immunotherapy against lung cancer.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Apigenin based nanoplatform achieves non-small cell lung cancer immunotherapy through glycolysis inhibition and photodynamic co-perturbation of organelles.Journal of nanobiotechnology · 2026Article
- Aggregation-Induced Emission Luminogens: Emerging Theranostic Platforms for Pulmonary Diseases.Luminescence : the journal of biological and chemical luminescence · 2026Review
- Engineering design of platelet-mimicking therapeutic systems: multilevel biomimicry, gating strategies, and translational boundaries.Frontiers in bioengineering and biotechnology · 2026Review
- Breaking the siege of hypoxia and lactate: carrier-free flexible dual-enzyme protein vesicle to ignite photodynamic-immune storm in head and neck squamous cell carcinoma.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer has become the leading cause of cancer related death worldwidely. Nowadays, immune checkpoint inhibitor (ICI) plays an important part in the treatment of lung cancer. However, immunologically cold tumor microenvironment (TME) hinders the therapeutic effect of ICIs. Herein, immunomodulating platelet-mimicking nanoparticles (DM@PM NPs) were designed by encapsulating the aggregation-induced emission (AIE) photosensitizer DTZ-TPA-DCN with acidic-sensitive bond modified DSPE-PEG-MET (MET, metformin) and then coating with a platelet membrane (PM). Notably, DM@PM NPs can selectively accumulate in tumor profiting from the tumor-targeting and antiphagocytic capabilities of PM. In the acidic tumor tissues, the acidic-sensitive released MET of DSPE-PEG-MET plays as a kind of ICI and degrades PD-L1 expression in TME. MET also facilitates AIE photosensitizer induced photodynamic therapy (PDT) via blocking mitochondrial oxidative phosphorylation, thus dramatically promotes immunogenic cell death (ICD) of tumor cells which could convert cold tumor to hot and facilitates MET realizing enhanced immunotherapy against cancer in turn. What's more, sub-lethal ROS induced by DM@PM NPs could also directly activate immune cells. Overall, we proposed an intelligent and cross-regulatory platelet-mimicking drug loading nano-carrier that could achieve photodynamic immunotherapy against in situ and distant tumors, which provides a potential for clinical therapy of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.